Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of JNJ-95475939 in adults with moderate to severe atopic dermatitis
2024-517814-13-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of JNJ-95475939 in atopic dermatitis (AD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: EASI 75 at Week 12. Started Apr 2025; status: completed.
02
Drugs
JNJ-95475939
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2024-517814-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517814-13-00.